Amendments to the Patented Medicines Regulations (PMR) came into force on July 1 after multiple delays, creating a new basket of reference countries for the Patented Medicine Prices Review Board (PMPRB) to use when assessing whether the price of a patented medicine is “excessive” in Canada. The PMPRB has not yet published new guidelines to operationalize the amendments, and has proposed a “status quo” approach for price assessments until new guidelines are in place in this interim period.
Please see our past bulletins on PMPRB for more information on the history of the amendments to the PMR and ongoing litigation involving PMPRB1.
To discuss these issues, please contact the author(s).
This publication is a general discussion of certain legal and related developments and should not be relied upon as legal advice. If you require legal advice, we would be pleased to discuss the issues in this publication with you, in the context of your particular circumstances.
For permission to republish this or any other publication, contact Janelle Weed.
© 2024 by Torys LLP.
All rights reserved.